CLINICAL_TRIALS
trial_result
· 2015-06-03
Clinical Trial Update: Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients [Phase 3]
Summary
Phase 3 trial evaluating prophylactic maribavir to prevent CMV disease in stem cell transplant recipients has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Shire | Conditions: Cytomegalovirus Infections | Phase 3 | Status: COMPLETED | Results posted: 2015-06-03